Developer docs
API playgroundTry for free, no card

Search company profiles

Avalyn Pharma

Full company profile

uuid00004ph

Namestring
Avalyn Pharma
Legal namestring
Avalyn Pharma Inc.
Company typeenum
Public
Founded yearint
2011
Descriptiontext

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled therapies for rare respiratory diseases, with a primary focus on idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), which together affect approximately 300,000 patients per year in the US and represent a global market projected to grow from roughly $3B (IPF alone) to $7B by 2035. The company's core technology is an inhaled aerosol drug-delivery platform that reformulates two validated, commercially successful anti-fibrotic small molecules — pirfenidone (marketed as Esbriet) and nintedanib (marketed as Ofev) — into aerosolized soft-mist formulations administered via the approved PARI eFlow handheld nebulizer. The lead candidate AP01 is inhaled pirfenidone (currently in a 375-patient Phase 2b MIST trial for PPF), AP02 is inhaled nintedanib (currently in the 160-patient Phase 2 AURA trial for IPF), and AP03 is a preclinical fixed-dose inhaled combination of both drugs that is not feasible orally due to additive systemic side effects.

The strategic rationale is to deliver higher lung drug concentrations than oral therapy while keeping systemic exposure well below oral levels, thereby reducing the GI, hepatic, and photosensitivity side effects that drive dose reductions and discontinuation with the oral drugs. Avalyn has built long-term safety data on inhaled pirfenidone through the ATLAS Phase 1b study and open-label extension, now extending past 240+ weeks (4+ years), and has assembled an 18-investor syndicate led by Suvretta Capital Management, SR One, Catalio Capital, and Novo Holdings, with a $100M Series D in July 2025 and a $345M Nasdaq IPO in April–May 2026 at an implied ~$1.1B market capitalization.

The business model is pre-revenue: Avalyn generates no product revenue today, reported a net loss of $85.2M in 2025, and is investing IPO proceeds in late-stage clinical development and pre-commercial buildout. Future revenue, contingent on regulatory approval, is expected to follow a specialty-pharma / orphan-drug pricing model for rare lung disease therapeutics, distributed through a planned direct specialty sales force targeting pulmonologists, ILD centers, and specialty pharmacies, supported by an 17+ patient and medical-organization partnership network and two Patient Advisory Councils.

Short descriptiontext

Avalyn Pharma is a clinical-stage biopharma developing inhaled reformulations of pirfenidone and nintedanib for patients with idiopathic and progressive pulmonary fibrosis, delivered via nebulizer. The company is publicly traded on Nasdaq (AVLN) and pre-revenue, with three programs in Phase 2b, Phase 2, and preclinical development.

Operating statusenum
Ipo
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
inhaled therapeutics, pulmonary fibrosis treatment, clinical-stage biopharma, aerosol drug delivery, interstitial lung disease
Industry1 code
PRIMARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Inhaled Pulmonary Fibrosis Therapeutics
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-revenue clinical-stage development
TypeSubscription Recurring
Description

Avalyn is a clinical-stage biopharmaceutical company with no approved products; it currently generates no product revenue. Future revenue is expected to come from commercialization of its inhaled therapeutic candidates (AP01, AP02, AP03) in rare respiratory diseases once regulatory approval is obtained.

avalynpharma.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Others, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled reformulations of two validated anti-fibrotic drugs — pirfenidone (AP01) and nintedanib (AP02) — plus a preclinical fixed-dose inhaled combination of the two (AP03), for delivery via the approved PARI eFlow handheld nebulizer to treat idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF), and other interstitial lung diseases. Its lead candidates aim to achieve higher lung drug exposure with significantly lower systemic toxicity than the corresponding oral therapies, and the company has no approved or commercialized products as of the IPO in May 2026.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 100 mg BID dose of inhaled pirfenidone (AP01) achieved near-stabilization of lung function over 48 weeks of treatment in the Phase 1b ATLAS study (West et al., 2023).
+4 more records
Product and service3 records
1AP01 (Inhaled Pirfenidone)
CategoryInhaled anti-fibrotic therapy — pirfenidone reformulation for IPF and PPF
Description

AP01 is Avalyn's lead clinical-stage program: an aerosolized soft-mist formulation of pirfenidone delivered via the approved PARI eFlow handheld nebulizer. It is being developed for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), with the goal of achieving higher anti-fibrotic drug exposure in diseased lung tissue while minimizing the systemic side effects (GI, hepatic, photosensitivity) that limit oral pirfenidone (Esbriet).

2AP02 (Inhaled Nintedanib)
CategoryInhaled anti-fibrotic therapy — nintedanib reformulation for IPF
Description

AP02 is Avalyn's second clinical-stage program: an aerosolized soft-mist formulation of nintedanib (a tyrosine kinase inhibitor) delivered via the approved PARI eFlow handheld nebulizer for direct lung delivery. It is being developed for IPF, with the goal of avoiding the systemic toxicities (diarrhea, hyperbilirubinemia, liver injury) associated with oral nintedanib (Ofev) while maintaining anti-fibrotic effect in diseased lung tissue.

3AP03 (Inhaled Pirfenidone + Nintedanib Fixed-Dose Combination)
CategoryInhaled fixed-dose combination anti-fibrotic therapy for IPF/PPF/ILDs
Description

AP03 is Avalyn's preclinical-stage program: a fixed-dose combination of pirfenidone and nintedanib delivered as an inhaled aerosol via the PARI eFlow nebulizer. It is designed to enable combination anti-fibrotic therapy that has not been feasible orally because of additive systemic side effects of the two drugs, while still delivering the combination directly to the lung.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership20 partners
Strategic tierCoreTypeGTM or Marketing Partner
Description

Patient/medical organization partner for education and program support for the PF community; relevant to Avalyn's primary indication and patient advocacy work.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Professional medical society partner; multiple Avalyn posters and presentations featured at ATS International Conference on AP01, AP02, devices, and patient journey work.

Strategic tierMajorTypeGTM or Marketing Partner
Description

Patient/medical organization partner supporting education and programs for patients, families, and care partners affected by pulmonary fibrosis and other lung diseases.

Strategic tierMajorTypeGTM or Marketing Partner
Description

Medical society partner; Avalyn has presented multiple AP01 and AP02 posters and study-design updates at the ERS International Congress.

5The European Pulmonary Fibrosis Federation (EU-PFF)
Strategic tierMajorTypeGTM or Marketing Partner
Description

European patient-federation partner for PF community education and advocacy across Europe.

avalynpharma.com
Strategic tierMajorTypeGTM or Marketing Partner
Description

Canadian patient-foundation partner for PF patient education and support programs.

Strategic tierMajorTypeGTM or Marketing Partner
Description

UK-based PF patient organization partner supporting the patient community.

Strategic tierMajorTypeGTM or Marketing Partner
Description

US professional medical society partner for clinician education and PF resources.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Canadian respiratory society partner for clinician engagement and educational resources.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Australian patient/medical organization partner for lung-disease education and community support.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Patient-organization partner for sarcoidosis awareness and education, relevant to ILD indications Avalyn's pipeline addresses.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Patient-organization partner for myositis-ILD education; relevant to PPF and connective-tissue disease-associated ILD populations.

13National Scleroderma Foundation
Strategic tierMinorTypeGTM or Marketing Partner
Description

Patient-organization partner for scleroderma-ILD community; relevant to connective-tissue disease-associated PPF populations.

avalynpharma.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Patient-advocacy partner serving the pulmonary fibrosis community.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Medical research foundation partner relevant to rheumatology-associated ILD populations.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Patient-organization partner for vasculitis-ILD community support and education.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Patient-advocacy partner for the PF community, based in Pennsylvania.

Strategic tierCoreTypeTechnology or Integration
Description

Avalyn's lead clinical programs (AP01 and AP02) are delivered via the approved PARI eFlow® handheld nebulizer system. PARI is referenced in the clinical-trial descriptions for the MIST and AP02 Phase 1b studies as the device partner for inhaled delivery.

19IPAC: Idiopathic Pulmonary Fibrosis Patient Advisory Council
Strategic tierCoreTypeStrategic or Co-development Partner
Description

One of two Avalyn Patient Advisory Councils (along with PPAC). The IPAC integrates patient and care-partner insights into study design, medicine development, and trial participation for IPF.

avalynpharma.com
20PPAC: Progressive Pulmonary Fibrosis Patient Advisory Council
Strategic tierCoreTypeStrategic or Co-development Partner
Description

One of two Avalyn Patient Advisory Councils. The PPAC integrates patient and care-partner insights into study design, medicine development, and trial participation for PPF.

avalynpharma.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biopharma developing novel therapies for IPF and other fibrotic diseases (lead asset bexotegrast). Comparable because it targets the same primary indication (IPF/PPF) and competes for the same pulmonologist/ILD-center patient population as Avalyn's AP01 and AP02.

TypeBroad incumbent
Description

Established rare-disease pulmonary company with Tyvaso DPI (inhaled treprostinil) approved for PAH and PH-ILD. Comparable as a broad incumbent in inhaled/respiratory therapeutics for fibrotic lung disease with a commercial specialty-pharma infrastructure that Avalyn aspires to build.

3Boehringer Ingelheim
TypeBroad incumbent
Description

Marketer of Ofev (nintedanib), one of only two approved oral anti-fibrotic drugs for IPF and the reference molecule for Avalyn's AP02 program. Comparable as the dominant incumbent in IPF whose physician, payer, and KOL relationships Avalyn must overcome commercially.

TypeBroad incumbent
Description

Marketer of Esbriet (pirfenidone), the other approved oral anti-fibrotic drug for IPF and reference molecule for Avalyn's AP01 program. Comparable as a major biopharma incumbent whose launch infrastructure Avalyn's commercial team (led by ex-ESBRIET US launch lead) is designed to compete against.

TypeEmerging player
Description

Late-stage inhaled-therapeutics company with commercial rare-disease respiratory assets (e.g., ARIKAYCE for MAC lung disease and the Phase 3 brensocatib program). Comparable as a company that has scaled an inhaled-therapeutics platform and a specialty-pharma commercial model for serious lung diseases — a credible template for Avalyn's evolution.

TypeDirect peer
Description

Late-stage respiratory therapeutics company developing ensifentrine for COPD and other lung diseases. Comparable as a clinical-stage respiratory company pursuing FDA approval of a differentiated inhaled therapy for serious chronic lung disease, with similar regulatory and commercialization trajectory.

TypeDirect peer
Description

Biopharmaceutical company that has developed therapeutics targeting fibrotic diseases including IPF (historical pamrevlumab program). Comparable as a clinical-stage company targeting IPF/ILD with novel mechanisms and competing for the same pulmonologist/ILD-center prescriber base.

TypeEmerging player
Description

Roivant-affiliated clinical-stage biopharma developing therapies for sarcoidosis and other inflammatory/ILDs. Comparable as a Roivant-platform emerging respiratory/ILD company pursuing orphan indications that overlap with Avalyn's broader ILD strategy.

TypeEmerging player
Description

Clinical-stage inhaled therapeutics company developing liposomal aerosol formulations for serious lung diseases. Comparable as an emerging inhaled-drug-delivery player; several Avalyn executives (e.g., COO Melissa Rhodes) previously led development there.

TypeOthers
Description

Roivant-affiliated rare respiratory/ILD company where Avalyn CEO Lyn Baranowski and other Avalyn executives previously led development. Comparable as a strategically related rare-respiratory biopharma platform and historical source of Avalyn's talent base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Avalyn Pharma

Inhaled Pulmonary Fibrosis Therapeuticsavalynpharma.com

Avalyn Pharma is a clinical-stage biopharma developing inhaled reformulations of pirfenidone and nintedanib for patients with idiopathic and progressive pulmonary fibrosis, delivered via nebulizer. The company is publicly traded on Nasdaq (AVLN) and pre-revenue, with three programs in Phase 2b, Phase 2, and preclinical development.

What Avalyn Pharma does

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled therapies for rare respiratory diseases, with a primary focus on idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), which together affect approximately 300,000 patients per year in the US and represent a global market projected to grow from roughly $3B (IPF alone) to $7B by 2035. The company's core technology is an inhaled aerosol drug-delivery platform that reformulates two validated, commercially successful anti-fibrotic small molecules — pirfenidone (marketed as Esbriet) and nintedanib (marketed as Ofev) — into aerosolized soft-mist formulations administered via the approved PARI eFlow handheld nebulizer. The lead candidate AP01 is inhaled pirfenidone (currently in a 375-patient Phase 2b MIST trial for PPF), AP02 is inhaled nintedanib (currently in the 160-patient Phase 2 AURA trial for IPF), and AP03 is a preclinical fixed-dose inhaled combination of both drugs that is not feasible orally due to additive systemic side effects.

The strategic rationale is to deliver higher lung drug concentrations than oral therapy while keeping systemic exposure well below oral levels, thereby reducing the GI, hepatic, and photosensitivity side effects that drive dose reductions and discontinuation with the oral drugs. Avalyn has built long-term safety data on inhaled pirfenidone through the ATLAS Phase 1b study and open-label extension, now extending past 240+ weeks (4+ years), and has assembled an 18-investor syndicate led by Suvretta Capital Management, SR One, Catalio Capital, and Novo Holdings, with a $100M Series D in July 2025 and a $345M Nasdaq IPO in April–May 2026 at an implied ~$1.1B market capitalization.

The business model is pre-revenue: Avalyn generates no product revenue today, reported a net loss of $85.2M in 2025, and is investing IPO proceeds in late-stage clinical development and pre-commercial buildout. Future revenue, contingent on regulatory approval, is expected to follow a specialty-pharma / orphan-drug pricing model for rare lung disease therapeutics, distributed through a planned direct specialty sales force targeting pulmonologists, ILD centers, and specialty pharmacies, supported by an 17+ patient and medical-organization partnership network and two Patient Advisory Councils.

Avalyn Pharma firmographics

Firmographics
Name
Avalyn Pharma
Legal name
Avalyn Pharma Inc.
Website
https://avalynpharma.com
Company type
Public
Founded year
2011
Operating status
Ipo
Headcount range
51–100 employees
Short description
Avalyn Pharma is a clinical-stage biopharma developing inhaled reformulations of pirfenidone and nintedanib for patients with idiopathic and progressive pulmonary fibrosis, delivered via nebulizer. The company is publicly traded on Nasdaq (AVLN) and pre-revenue, with three programs in Phase 2b, Phase 2, and preclinical development.
Ownership category
akta.pro rank

Avalyn Pharma industry classification

Industry
Product category
Inhaled Pulmonary Fibrosis Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Inhaled therapeutics
  • Pulmonary fibrosis treatment
  • Clinical-stage biopharma
  • Aerosol drug delivery
  • Interstitial lung disease

Where Avalyn Pharma is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Avalyn Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others, Marketing or Sales, Infrastructure

Revenue model

  1. Pre-revenue clinical-stage development: Avalyn is a clinical-stage biopharmaceutical company with no approved products; it currently generates no product revenue. Future revenue is expected to come from commercialization of its inhaled therapeutic candidates (AP01, AP02, AP03) in rare respiratory diseases once regulatory approval is obtained.

Go-to-market motion4 records

Distribution channels3 records

Marketing channels8 records

Avalyn Pharma product offering

Product offering

Core offering

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled reformulations of two validated anti-fibrotic drugs — pirfenidone (AP01) and nintedanib (AP02) — plus a preclinical fixed-dose inhaled combination of the two (AP03), for delivery via the approved PARI eFlow handheld nebulizer to treat idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF), and other interstitial lung diseases. Its lead candidates aim to achieve higher lung drug exposure with significantly lower systemic toxicity than the corresponding oral therapies, and the company has no approved or commercialized products as of the IPO in May 2026.

Differentiator

Problem solved

Functional benefit

Products and services

  • AP01 (Inhaled Pirfenidone) AP01 is Avalyn's lead clinical-stage program: an aerosolized soft-mist formulation of pirfenidone delivered via the approved PARI eFlow handheld nebulizer. It is being developed for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), with the goal of achieving higher anti-fibrotic drug exposure in diseased lung tissue while minimizing the systemic side effects (GI, hepatic, photosensitivity) that limit oral pirfenidone (Esbriet).
  • AP02 (Inhaled Nintedanib) AP02 is Avalyn's second clinical-stage program: an aerosolized soft-mist formulation of nintedanib (a tyrosine kinase inhibitor) delivered via the approved PARI eFlow handheld nebulizer for direct lung delivery. It is being developed for IPF, with the goal of avoiding the systemic toxicities (diarrhea, hyperbilirubinemia, liver injury) associated with oral nintedanib (Ofev) while maintaining anti-fibrotic effect in diseased lung tissue.
  • AP03 (Inhaled Pirfenidone + Nintedanib Fixed-Dose Combination) AP03 is Avalyn's preclinical-stage program: a fixed-dose combination of pirfenidone and nintedanib delivered as an inhaled aerosol via the PARI eFlow nebulizer. It is designed to enable combination anti-fibrotic therapy that has not been feasible orally because of additive systemic side effects of the two drugs, while still delivering the combination directly to the lung.

Quantifiable outcome

  • 100 mg BID dose of inhaled pirfenidone (AP01) achieved near-stabilization of lung function over 48 weeks of treatment in the Phase 1b ATLAS study (West et al., 2023).
  • +4 more outcomes

Companies that use Avalyn Pharma

Customer profile

Segments4 records

Ideal customer profiles4 records

Avalyn Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Avalyn Pharma partnerships and signals

Strategic signal

Partnerships

20 partnerships are on record, tiered core, major and minor.

  • Pulmonary Fibrosis Foundation (PFF)coreGTM or Marketing PartnerPatient/medical organization partner for education and program support for the PF community; relevant to Avalyn's primary indication and patient advocacy work.
  • American Thoracic Society (ATS)coreGTM or Marketing PartnerProfessional medical society partner; multiple Avalyn posters and presentations featured at ATS International Conference on AP01, AP02, devices, and patient journey work.
  • American Lung Association (ALA)majorGTM or Marketing PartnerPatient/medical organization partner supporting education and programs for patients, families, and care partners affected by pulmonary fibrosis and other lung diseases.
  • European Respiratory Society (ERS)majorGTM or Marketing PartnerMedical society partner; Avalyn has presented multiple AP01 and AP02 posters and study-design updates at the ERS International Congress.
  • The European Pulmonary Fibrosis Federation (EU-PFF)majorGTM or Marketing PartnerEuropean patient-federation partner for PF community education and advocacy across Europe.
  • Canadian Pulmonary Fibrosis Foundation (CPFF)majorGTM or Marketing PartnerCanadian patient-foundation partner for PF patient education and support programs.
  • Action for Pulmonary FibrosismajorGTM or Marketing PartnerUK-based PF patient organization partner supporting the patient community.
  • American College of CHEST Physicians (CHEST)majorGTM or Marketing PartnerUS professional medical society partner for clinician education and PF resources.
  • Canadian Thoracic SocietyminorGTM or Marketing PartnerCanadian respiratory society partner for clinician engagement and educational resources.
  • Lung Foundation AustraliaminorGTM or Marketing PartnerAustralian patient/medical organization partner for lung-disease education and community support.
  • Foundation for Sarcoidosis ResearchminorGTM or Marketing PartnerPatient-organization partner for sarcoidosis awareness and education, relevant to ILD indications Avalyn's pipeline addresses.
  • The Myositis AssociationminorGTM or Marketing PartnerPatient-organization partner for myositis-ILD education; relevant to PPF and connective-tissue disease-associated ILD populations.
  • National Scleroderma FoundationminorGTM or Marketing PartnerPatient-organization partner for scleroderma-ILD community; relevant to connective-tissue disease-associated PPF populations.
  • PF WarriorsminorGTM or Marketing PartnerPatient-advocacy partner serving the pulmonary fibrosis community.
  • Rheumatology Research FoundationminorGTM or Marketing PartnerMedical research foundation partner relevant to rheumatology-associated ILD populations.
  • Vasculitis FoundationminorGTM or Marketing PartnerPatient-organization partner for vasculitis-ILD community support and education.
  • Wescoe Foundation for Pulmonary FibrosisminorGTM or Marketing PartnerPatient-advocacy partner for the PF community, based in Pennsylvania.
  • PARI (eFlow® nebulizer system)coreTechnology or IntegrationAvalyn's lead clinical programs (AP01 and AP02) are delivered via the approved PARI eFlow® handheld nebulizer system. PARI is referenced in the clinical-trial descriptions for the MIST and AP02 Phase 1b studies as the device partner for inhaled delivery.
  • IPAC: Idiopathic Pulmonary Fibrosis Patient Advisory CouncilcoreStrategic or Co-development PartnerOne of two Avalyn Patient Advisory Councils (along with PPAC). The IPAC integrates patient and care-partner insights into study design, medicine development, and trial participation for IPF.
  • PPAC: Progressive Pulmonary Fibrosis Patient Advisory CouncilcoreStrategic or Co-development PartnerOne of two Avalyn Patient Advisory Councils. The PPAC integrates patient and care-partner insights into study design, medicine development, and trial participation for PPF.

Scale indicators16 records

Recent moves7 records

Expansion highlights6 records

Avalyn Pharma competitors and assessment

Company assessment

Direct peers

  • Pliant Therapeutics: Clinical-stage biopharma developing novel therapies for IPF and other fibrotic diseases (lead asset bexotegrast). Comparable because it targets the same primary indication (IPF/PPF) and competes for the same pulmonologist/ILD-center patient population as Avalyn's AP01 and AP02.
  • Verona Pharma: Late-stage respiratory therapeutics company developing ensifentrine for COPD and other lung diseases. Comparable as a clinical-stage respiratory company pursuing FDA approval of a differentiated inhaled therapy for serious chronic lung disease, with similar regulatory and commercialization trajectory.
  • FibroGen: Biopharmaceutical company that has developed therapeutics targeting fibrotic diseases including IPF (historical pamrevlumab program). Comparable as a clinical-stage company targeting IPF/ILD with novel mechanisms and competing for the same pulmonologist/ILD-center prescriber base.

Broad incumbents

  • United Therapeutics: Established rare-disease pulmonary company with Tyvaso DPI (inhaled treprostinil) approved for PAH and PH-ILD. Comparable as a broad incumbent in inhaled/respiratory therapeutics for fibrotic lung disease with a commercial specialty-pharma infrastructure that Avalyn aspires to build.
  • Boehringer Ingelheim: Marketer of Ofev (nintedanib), one of only two approved oral anti-fibrotic drugs for IPF and the reference molecule for Avalyn's AP02 program. Comparable as the dominant incumbent in IPF whose physician, payer, and KOL relationships Avalyn must overcome commercially.
  • Genentech / Roche: Marketer of Esbriet (pirfenidone), the other approved oral anti-fibrotic drug for IPF and reference molecule for Avalyn's AP01 program. Comparable as a major biopharma incumbent whose launch infrastructure Avalyn's commercial team (led by ex-ESBRIET US launch lead) is designed to compete against.

Emerging players

  • Insmed Incorporated: Late-stage inhaled-therapeutics company with commercial rare-disease respiratory assets (e.g., ARIKAYCE for MAC lung disease and the Phase 3 brensocatib program). Comparable as a company that has scaled an inhaled-therapeutics platform and a specialty-pharma commercial model for serious lung diseases — a credible template for Avalyn's evolution.
  • Kinevant Sciences: Roivant-affiliated clinical-stage biopharma developing therapies for sarcoidosis and other inflammatory/ILDs. Comparable as a Roivant-platform emerging respiratory/ILD company pursuing orphan indications that overlap with Avalyn's broader ILD strategy.
  • Aerami Therapeutics: Clinical-stage inhaled therapeutics company developing liposomal aerosol formulations for serious lung diseases. Comparable as an emerging inhaled-drug-delivery player; several Avalyn executives (e.g., COO Melissa Rhodes) previously led development there.

Others

  • Altavant Sciences (Enzyvant): Roivant-affiliated rare respiratory/ILD company where Avalyn CEO Lyn Baranowski and other Avalyn executives previously led development. Comparable as a strategically related rare-respiratory biopharma platform and historical source of Avalyn's talent base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Avalyn Pharma social profiles

Digital presence

Avalyn Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Avalyn Pharma leadership team

Management profile

Number of profiles

Profiles18 records

Avalyn Pharma funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Avalyn Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avalyn Pharma

What does Avalyn Pharma do?

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled reformulations of two validated anti-fibrotic drugs — pirfenidone (AP01) and nintedanib (AP02) — plus a preclinical fixed-dose inhaled combination of the two (AP03), for delivery via the approved PARI eFlow handheld nebulizer to treat idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF), and other interstitial lung diseases. Its lead candidates aim to achieve higher lung drug exposure with significantly lower systemic toxicity than the corresponding oral therapies, and the company has no approved or commercialized products as of the IPO in May 2026.

Is Avalyn Pharma a public or private company?

Avalyn Pharma is a public company. It is classified as public and is currently ipo.

When was Avalyn Pharma founded?

Avalyn Pharma was founded in 2011. It employs 51 to 100 people.

Where is Avalyn Pharma based?

Avalyn Pharma is headquartered in Boston, United States, in the North America region.

How does Avalyn Pharma make money?

One revenue line is on record: pre-revenue clinical-stage development.

Who are Avalyn Pharma's main competitors?

Direct peers on record are Pliant Therapeutics, Verona Pharma and FibroGen. Broad incumbents are United Therapeutics, Boehringer Ingelheim and Genentech / Roche. Emerging players are Insmed Incorporated, Kinevant Sciences and Aerami Therapeutics. Altavant Sciences (Enzyvant) is listed as an others.

Does Avalyn Pharma have an API?

No public API is recorded for Avalyn Pharma.

What industry is Avalyn Pharma in?

Avalyn Pharma's product category is Inhaled Pulmonary Fibrosis Therapeutics. Its primary akta.pro industry code is HLAIAIAG, Pulmonary Hypertension & Rare Pulmonary Disease Therapies. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ChartmillAvalyn Pharma Inc (NASDAQ:AVLN) Q3 Loss Narrower Than Expected as 2027 Pipeline Catalysts Remain in FocusAvalyn Pharma reported a Q3 2026 net loss of $0.67 per share, narrower than the $0.7276 consensus, with zero revenue. R&D and G&A expenses rose to $25.5M and $7.6M, respectively, while cash reached $386.6M, funding operations into 2029. The company expects data from all three programs in 2027.Quiver QuantitativeAVALYN PHARMA ($AVLN) Releases Q3 2026 Earnings | AVLN Stock NewsAvalyn Pharma reported Q3 2026 earnings of -$0.67 per share, beating estimates of -$0.73, with revenue of $0. The stock fell 2.42% after market open. Analysts have set a median price target of $53.0.MarketScreenerAvalyn Pharma Q3 Net Loss NarrowsAvalyn Pharma reported a Q3 net loss of $0.67 per share, beating the $0.59 loss estimated by FactSet. The company's stock rose 1.44% on the news, with a 5-day change of 31.62 USD.TradingViewAvalyn Pharma Reports Q3 2026 Results, Ends Quarter With $386.6 MillionAvalyn Pharma reported a Q3 2026 net loss of $29.7 million, up from $23.6 million a year earlier, with R&D expenses of $25.5 million. The company ended the quarter with $386.6 million in cash and expects to fund operations into 2029.Seeking AlphaAvalyn Pharma Inc. (AVLN) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference TranscriptAvalyn Pharma presented at the Guggenheim Healthcare Innovation Conference, with CEO Lyn Baranowski and CFO Doug Carlson discussing the company's focus on pulmonary fibrosis. The company is clinical stage, noting three approved drugs for the disease, two of which have been on the market for about 10 years and are poorly tolerated.The National Law ReviewBiotech is One of the Few Sectors Where IPO Still Works as FinancBiotech IPOs remain viable as investors diversify from AI-heavy portfolios, with Kailera and Avalyn exceeding funding targets. Specialist capital is flowing into obesity, oncology, and RNA therapeutics, while M&A provides a backstop. The outlook for 2027 is selective, with companies needing differentiated science and credible sponsors.MarketScreenerCertain Warrants of Avalyn Pharma Inc. are subject to a Lock-Up Agreement Ending on 27-OCT-2026.Certain warrants of Avalyn Pharma are subject to a lock-up agreement ending 27-Oct-2026, covering 181 days from 29-Apr-2026. The company, a clinical-stage biopharmaceutical firm, has three approved oral antifibrotic therapies and is advancing inhaled formulations AP01 and AP02 in clinical trials.MarketScreener25,150,636 Common Stock of Avalyn Pharma Inc. are subject to a Lock-Up Agreement Ending on 27-OCT-2026.Avalyn Pharma's 25,150,636 common shares are locked up until 27-Oct-2026, per a 181-day agreement. The company has three approved antifibrotics and two inhaled candidates, with AP02 in a Phase II trial.MarketBeatAvalyn Pharma Inc. (NASDAQ:AVLN) Stock Now Rated "Moderate Buy" by Sell-Side BrokeragesAvalyn Pharma shares received a consensus "Moderate Buy" rating from seven analysts, with an average price target of $60.00. The company reported a quarterly loss of $0.98 per share, beating the consensus estimate of $1.03. Analysts forecast a fiscal-year loss of $3.86 per share.MarketBeatAvalyn Pharma Inc.'s Lock-Up Period Set To End on October 27th (NASDAQ:AVLN)Avalyn Pharma's lock-up period expires on October 27th, following a $300 million public offering of 16.67 million shares. Analysts rate the stock a Moderate Buy with an average price target of $60.00, and the company reported a loss of $0.98 per share for the quarter.